GSK, a big UK Pharma, has announced the start of a phase II study to evaluate the efficacy and safety of its candidate, GSK3196165.
The trial will enroll 40 patients with hand osteoarthritis – a condition that damages joints, leading to pain and stiffness.
GSK3196165 is a monoclonal antibody that acts as anti-granulocyte macrophage colony-stimulating factor (anti GM-CSF). GM-CSF is a protein secreted by cells of the immune system, involved in cell signalling and inflammatory response.
The monoclonal antibody now in trials was actually discovered and engineered by MorphoSys, being licensed to GSK in 2013.